Differences in the Renal Accumulation of Radiogallium-Labeled (Glu) Peptides Containing Different Optical Isomers of Glutamic Acid

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Sep 14

PMID 39274840

Authors

Kazuma Ogawa

Kota Nishizawa

Kenji Mishiro

Masayuki Munekane

Takeshi Fuchigami

Hiroaki Echigo

Hiroshi Wakabayashi

Seigo Kinuya

Affiliations

Soon will be listed here.

Abstract

Acidic amino acid peptides have a high affinity for bone. Previously, we demonstrated that radiogallium complex-conjugated oligo-acidic amino acids possess promising properties as bone-seeking radiopharmaceuticals. Here, to elucidate the effect of stereoisomers of Glu in Glu-containing peptides [(Glu)] on their accumulation in the kidney, the biodistributions of [Ga]Ga-,'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-,'-diacetic acid-conjugated (l-Glu) ([Ga]Ga-HBED-CC-(l-Glu)), [Ga]Ga-HBED-CC-(d-Glu), [Ga]Ga-HBED-CC-(dl-Glu), and [Ga]Ga-HBED-CC-(d-Glu-l-Glu) were compared. Although the accumulation of these compounds in the bone was comparable, their kidney accumulation and retention were strikingly different, with [Ga]Ga-HBED-CC-(d-Glu-l-Glu) exhibiting the lowest level of kidney accumulation among these compounds. Repeated d- and l-peptides may be a useful method for reducing renal accumulation in some cases.

References

Ogawa K, Mukai T, Arano Y, Otaka A, Ueda M, Uehara T . Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol. 2006; 33(4):513-20. DOI: 10.1016/j.nucmedbio.2006.03.006. View

Ben Azzouna R, Guez A, Benali K, Al-Shoukr F, Gonzalez W, Karoyan P . Synthesis, gallium labelling and characterization of P04087, a functionalized phosphatidylserine-binding peptide. EJNMMI Radiopharm Chem. 2018; 2(1):3. PMC: 5835976. DOI: 10.1186/s41181-016-0021-5. View

Jin W, Zhao R, Wang R, Choi S, Ploessl K, Alexoff D . Theranostic Agent Targeting Bone Metastasis: A Novel [Ga]Ga/[Lu]Lu-DOTA-HBED-bisphosphonate. J Med Chem. 2024; 67(6):4793-4803. DOI: 10.1021/acs.jmedchem.3c02372. View

Ogawa K, Nishizawa K, Mishiro K, Effendi N, Fuchigami T, Munekane M . Synthesis and Evaluation of Radiogallium Labeled Bone-Imaging Probes Using Oligo-γ-Carboxy Glutamic Acid Peptides as Carriers to Bone. Mol Pharm. 2024; 21(5):2375-2382. DOI: 10.1021/acs.molpharmaceut.3c01156. View

Uehara T, Jin Z, Ogawa K, Akizawa H, Hashimoto K, Nakayama M . Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones. Nucl Med Biol. 2007; 34(1):79-87. DOI: 10.1016/j.nucmedbio.2006.10.001. View

Ishizaki A, Mishiro K, Shiba K, Hanaoka H, Kinuya S, Odani A . Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives. Ann Nucl Med. 2019; 33(4):244-251. DOI: 10.1007/s12149-018-01326-5. View

Ogawa K, Saji H . Advances in drug design of radiometal-based imaging agents for bone disorders. Int J Mol Imaging. 2012; 2011:537687. PMC: 3246737. DOI: 10.1155/2011/537687. View

Ogawa K, Yu J, Ishizaki A, Yokokawa M, Kitamura M, Kitamura Y . Radiogallium Complex-Conjugated Bifunctional Peptides for Detecting Primary Cancer and Bone Metastases Simultaneously. Bioconjug Chem. 2015; 26(8):1561-70. DOI: 10.1021/acs.bioconjchem.5b00186. View

Ogawa K, Mukai T, Inoue Y, Ono M, Saji H . Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med. 2006; 47(12):2042-7. View

10.

Ogawa K, Mukai T, Asano D, Kawashima H, Kinuya S, Shiba K . Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. J Nucl Med. 2007; 48(1):122-7. View

11.

Suzuki K, Satake M, Suwada J, Oshikiri S, Ashino H, Dozono H . Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging. Nucl Med Biol. 2011; 38(7):1011-8. DOI: 10.1016/j.nucmedbio.2011.02.015. View

12.

Ogawa K, Ishizaki A, Takai K, Kitamura Y, Kiwada T, Shiba K . Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers. PLoS One. 2014; 8(12):e84335. PMC: 3877283. DOI: 10.1371/journal.pone.0084335. View

13.

Ogawa K, Mukai T, Arano Y, Ono M, Hanaoka H, Ishino S . Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem. 2005; 16(4):751-7. DOI: 10.1021/bc040249w. View

14.

Ogawa K, Ishizaki A, Takai K, Kitamura Y, Makino A, Kozaka T . Evaluation of Ga-DOTA-(D-Asp) as bone imaging agents: D-aspartic acid peptides as carriers to bone. Sci Rep. 2017; 7(1):13971. PMC: 5656653. DOI: 10.1038/s41598-017-14149-7. View

15.

Ishizaki J, Waki Y, Takahashi-Nishioka T, Yokogawa K, Miyamoto K . Selective drug delivery to bone using acidic oligopeptides. J Bone Miner Metab. 2008; 27(1):1-8. DOI: 10.1007/s00774-008-0004-z. View

16.

Arano Y, Fujioka Y, Akizawa H, Ono M, Uehara T, Wakisaka K . Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res. 1999; 59(1):128-34. View

17.

Gupta S, Singla S, Thakral P, Bal C . Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE. Clin Nucl Med. 2013; 38(3):188-94. DOI: 10.1097/RLU.0b013e3182814ac1. View

18.

Ogawa K, Kawashima H, Shiba K, Washiyama K, Yoshimoto M, Kiyono Y . Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. Nucl Med Biol. 2009; 36(2):129-35. DOI: 10.1016/j.nucmedbio.2008.11.007. View

19.

Suzuki H, Araki M, Tatsugi K, Ichinohe K, Uehara T, Arano Y . Reduction of the Renal Radioactivity of In-DOTA-Labeled Antibody Fragments with a Linkage Cleaved by the Renal Brush Border Membrane Enzymes. J Med Chem. 2023; 66(13):8600-8613. PMC: 10350918. DOI: 10.1021/acs.jmedchem.3c00258. View

20.

Fellner M, Baum R, Kubicek V, Hermann P, Lukes I, Prasad V . PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging. 2010; 37(4):834. DOI: 10.1007/s00259-009-1355-y. View